# 111, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/111, Inc.). ## Overview 111, Inc. is a U.S.-listed healthcare commerce and services platform organized around China’s pharmaceutical supply chain. It operates online retail pharmacy, internet hospital, pharmacy-sourcing, and digital commercialization businesses that connect consumers, pharmacies, and pharmaceutical manufacturers through its 1 Pharmacy, 1 Clinic, and 1 Medicine platforms. ## Products & services • Online retail pharmacy services via 1 Pharmacy • Internet hospital services via 1 Clinic • Pharmacy sourcing platform via 1 Medicine • Virtual pharmacy network and cloud-based pharmacy services • Digital marketing, patient education, and pricing monitoring - **Online retail pharmacy** (45%) — Direct-to-consumer pharmaceutical sales and related healthcare products through the 1 Pharmacy channel. - **Marketplace service revenue** (25%) — Platform and service fees generated from marketplace, commercialization, and partner services. - **Internet hospital services** (10%) — Online consultation, e-prescription, and patient management services delivered through 1 Clinic. - **Supply chain and sourcing services** (15%) — Pharmacy sourcing, product distribution, and virtual pharmacy network services through 1 Medicine. - **Digital commercialization services** (5%) — Promotional, data, and brand-building services for pharmaceutical partners and pharmacies. - Online retail pharmacy services via 1 Pharmacy - Internet hospital services via 1 Clinic - Pharmacy sourcing platform via 1 Medicine - Virtual pharmacy network and cloud-based pharmacy services - Digital marketing, patient education, and pricing monitoring ## Customers 111 sells to both consumers seeking prescription and OTC pharmacy access and to offline pharmacies that use its sourcing and cloud-based tools. It also serves pharmaceutical manufacturers and strategic partners that buy commercialization, marketing, and distribution access across its platform. The business is built around demand from China’s pharmacy and healthcare ecosystem rather than from a single end market. - **Consumers** (primary) — Buy pharmaceuticals and online healthcare services through 1 Pharmacy and 1 Clinic for convenience and access. - **Offline pharmacies** (primary) — Buy sourcing, cloud tools, and virtual pharmacy network services to improve procurement and customer service. - **Pharmaceutical manufacturers** (primary) — Buy commercialization, digital marketing, and distribution access to reach pharmacies and end customers. - **Small and medium chain pharmacies** (secondary) — Buy promoted products and sourcing support to expand assortment and improve sell-through. - **Strategic healthcare partners** (secondary) — Buy patient education, data analytics, and pricing monitoring services. - Consumers buying medicines and healthcare services online - Offline pharmacies using sourcing and cloud-based services - Pharmaceutical companies seeking promotion and distribution reach - Strategic partners buying patient education and analytics services - SME chain pharmacies targeted by promotional product programs ## Geography The company is centered in China, where its online pharmacy, internet hospital, and pharmacy-network services are deployed. It is headquartered in the United States for listing purposes, but its commercial activity, customer base, and operating footprint are primarily in China. That geography ties the business closely to Chinese healthcare regulation, pharmacy distribution practices, and digital health adoption. - Primary operating market is China - Services are delivered through China-based healthcare and pharmacy channels - Shanghai is a disclosed operating and contact location - NASDAQ listing and U.S. incorporation support capital access - China exposure drives regulatory and healthcare policy sensitivity ## Strategy 111 is moving toward a more asset-light, platform-oriented model that relies more on service revenue and less on balance-sheet-heavy fulfillment. It is also broadening SKU coverage, partner relationships, and digital commercialization tools to deepen pharmacy penetration and improve monetization across the supply chain. - **Asset-light platform transition** (short-term) — Reduces fulfillment intensity and shifts the model toward service and commission revenue. - **Broaden product and partner network** (medium-term) — More SKUs and distribution rights improve pharmacy reach and strengthen monetization. - **Improve digital commercialization** (medium-term) — Digital marketing and analytics help pharmaceutical partners reach downstream buyers more effectively. - Shift toward an asset-light, platform-oriented operating model - Increase marketplace service revenue and recurring commission income - Expand SKU assortment and promotional product coverage - Strengthen partnerships with online platforms and pharmaceutical companies - Use AI and digital tools to improve operating efficiency ## Risks 111’s business depends on Chinese healthcare regulation, pharmacy channel economics, and continued participation by pharmacies, consumers, and drug makers on its platform. Its transition to a platform model also depends on execution, while its balance sheet and redemption obligations create additional financial risk if cash generation is uneven. - **China healthcare and online pharmacy regulation** [high] — The core business operates in Chinese digital health and drug commerce, which is policy-sensitive. - **Platform transition execution** [high] — The company is shifting revenue mix and operating model, which can disrupt growth and service delivery if not managed well. - **Redemption obligation and liquidity strain** [high] — Investor redemption liabilities and cash outflows can reduce financial flexibility. - **Partner concentration and supply chain dependence** [medium] — Distribution rights and promotional performance rely on pharmaceutical company cooperation and pharmacy demand. - **Competitive pressure in online healthcare** [medium] — The business competes on access, pricing, and platform reach in a crowded digital pharmacy market. - China regulatory and policy exposure in healthcare and online pharmacy - Execution risk in the move from fulfillment-heavy to asset-light model - Dependence on pharmaceutical partner relationships and product rights - Liquidity pressure from redemption obligations and cash usage - Competition from other online pharmacy and healthcare platforms ## Accounting Revenue is affected by the mix between product sales and service or marketplace revenue, which can change the timing and pattern of recognition. The company also has material judgment around redemption obligations, accrued liabilities, and share-based compensation, all of which can materially affect reported losses and balance-sheet presentation. - **Revenue recognition by business line** — Mix shift can change reported growth rates and margins. - **Redemption liabilities** — Affects current liabilities, liquidity, and loss presentation. - **Share-based compensation** — Can widen the gap between GAAP and adjusted results. - **Inventory and fulfillment accounting** — Can alter cost of revenue, operating expense, and working capital. - Revenue mix between products and marketplace services affects recognition timing - Promotional product sales can create quarter-to-quarter revenue variability - Redemption obligations affect accrued liabilities and liquidity presentation - Share-based compensation distorts GAAP versus non-GAAP profitability - Asset-light transition may change inventory and fulfillment accounting intensity --- *Last updated: 2026-09-28T11:57:26.419373+00:00*